Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 9;20(6):51.
doi: 10.1007/s11864-019-0646-1.

Cardiotoxicity of Contemporary Breast Cancer Treatments

Katherine Lee Chuy  1 , Anthony F Yu  2   3
Affiliations
Review

Cardiotoxicity of Contemporary Breast Cancer Treatments

Katherine Lee Chuy et al. Curr Treat Options Oncol. .

Abstract

Treatment-related cardiotoxicity remains a significant concern for breast cancer patients undergoing cancer treatment and extends into the survivorship period, with adverse cardiovascular (CV) outcomes further compounded by the presence of pre-existing CV disease or traditional CV risk factors. Awareness of the cardiotoxicity profiles of contemporary breast cancer treatments and optimization of CV risk factors are crucial in mitigating cardiotoxicity risk. Assessment of patient- and treatment-specific risk with appropriate CV surveillance is another key component of care. Mismatch between baseline cardiotoxicity risk and intensity of cardiotoxicity surveillance can lead to unnecessary downstream testing, increased healthcare expenditure, and interruption or discontinuation of potentially life-saving treatment. Efforts to identify early imaging and/or circulating biomarkers of cardiotoxicity and develop effective management strategies are needed to optimize the CV and cancer outcomes of breast cancer survivors.

Keywords: Breast cancer; Cardio-oncology; Cardiotoxicity.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Katherine Lee Chuy declares that she has no conflict of interest.

Anthony F. Yu has received compensation from Glenmark Pharmaceuticals, Takeda Oncology, Bristol-Myers Squibb, and Bayer for service as a consultant.

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. 10.3322/caac.21492. - DOI - PubMed
    1. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137(8):e30–66. 10.1161/CIR.0000000000000556 - DOI - PMC - PubMed

    2. This is the first American Heart Association scientific statement providing a comprehensive evidence-based discussion on the association between breast cancer and CVD.

    1. Abdel-Qadir H, Austin PC, Lee DS, Amir E, Tu JV, Thavendiranathan P, et al. A population-based study of cardiovascular mortality following early-stage breast cancer. JAMA Cardiol. 2017;2(1):88–93. 10.1001/jamacardio.2016.3841. - DOI - PubMed
    1. Hershman DL, Till C, Shen S, Wright JD, Ramsey SD, Barlow WE, et al. Association of cardiovascular risk factors with cardiac events and survival outcomes among patients with breast cancer enrolled in SWOG Clinical Trials. J Clin Oncol. 2018;36(26):2710–7. 10.1200/JCO,10.1200/JCO.2017. - DOI - PMC - PubMed
    1. Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, et al. Anthracyclines in early breast cancer: the ABC trials—USOR 06–090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017;35(23):2647–55. 10.1200/JCO,10.1200/JCO.2016. - DOI - PMC - PubMed

MeSH terms